Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema Results from the Pan-American Collaborative Retina Study Group at 6-Month Follow-up

Purpose: To report the 6-month anatomic and best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (Avastin) in patients with diabetic macular edema (DME). Design: Interventional retrospective multicenter study at 6 centers from 6 countries of patients with DME. Particip...

Descripción completa

Detalles Bibliográficos
Autores Principales: Arevalo, J. Fernando, Fromow-Guerra, Jans, Quiroz-Mercado, Hugo, Sanchez, Juan G., Wu, Lihteh, Maia, Mauricio, Berrocal, Maria H., Solis-Vivanco, Adriana, Farah, Michel E
Formato: Artículo (Article)
Lenguaje:Inglés (English)
Publicado: Elsevier 2007
Materias:
Acceso en línea:https://repository.urosario.edu.co/handle/10336/26225
https://doi.org/10.1016/j.ophtha.2006.12.028